By the time of this webinar, Congress will have passed and the President will have signed the most consequential drug pricing and benefit reform act since the ACA in 2010. Please join our experienced panel as they unpack the bill, explain its mechanics, and provide insight into its ramifications for drug and biologics manufacturers. The panel will consider the compliance and government program liability implications of the new law, focusing on:
- Medicare price negotiation for “high-priced” single source drugs
- Special treatment for biologics and biosimilars
- New Medicare drug inflation rebates
- Part D benefit redesign
For questions, contact Chayako Williams at email@example.com.
King & Spalding is an accredited provider of CLE credit in California, Georgia, Illinois, New York and Texas. We can issue reciprocal credit for attorneys licensed in Connecticut, Florida and New Jersey. We will apply for credit in Colorado, North Carolina and Virginia (subject to MCLE Board approval). For jurisdictions not listed, attendees are provided with a Universal Certificate of Attendance. New York licensed attorneys: Transitional/Appropriate for newly admitted and experienced attorneys. Financial aid is available for qualifying lawyers. For CLE-related questions, please contact Gisel Arias at firstname.lastname@example.org. King & Spalding, 1180 Peachtree Street NE, Atlanta, GA 30309. CA Provider #10947.